Incidence of Hemorrhagic Complications among Patients Treated with Thrombolytic in Erbil City, Iraq | ||
| Al- Anbar Medical Journal | ||
| Article 4, Volume 16, Issue 2, December 2020, Pages 35-39 PDF (284.59 K) | ||
| Document Type: Original articles | ||
| DOI: 10.33091/amj.2020.170955 | ||
| Authors | ||
| Ahmed F. Hammad; Imad T. Abdulhafed* ; Abdulsalam R. Awad | ||
| Department of Internal Medicine, Al-Ramadi Teaching Hospital, Anbar Health Directorate, Ramadi, Anbar, Iraq. | ||
| Abstract | ||
| Background: Recombinant tissue-type plasminogen activator is an option of treatment for suspected occlusive vascular thrombi and its sequel (transmural myocardial infarction, pulmonary embolism, and ischemic stroke). The most important concern associated with those patients is the fear of hemorrhagic complications. Objectives: To evaluate the incidence and risk factors of bleeding following the use of recombinant tissue-type plasminogen activator. Materials and Methods: This prospective study was conducted in the Intensive Care Units of Roj-halat Emergency Hospital and Rizgary Teaching Hospital in Erbil city/Iraq. The duration of the study was through the period from 1st of June, 2016 to 1st of March, 2017. A convenient sample of 100 patients was selected. The patients were followed after their admission to Intensive Care Units for 24 hours after their treatment with recombinant tissue-type plasminogen activator to explore their complications. Results: Bleeding complication represented 10% of patients treated with recombinant tissue-type plasminogen activator (50% for each major and minor bleeding). There was a significant association between increased age of patients treated with recombinant tissue-type plasminogen activator and bleeding (P-value = 0. 01). Patients with a history of hypertension, diabetes, and smoking were significantly associated with a bleeding complication of recombinant tissue-type plasminogen activator (P-value <0.05). Conclusions: The incidence of bleeding among patients after treatment with recombinant tissue-type plasminogen activator in the intensive care unit was acceptable. The age, diabetes, smoking, and hypertension were risk factors for increasing the bleeding complications in subjects treated with recombinant tissue-type plasminogen. | ||
| Keywords | ||
| Recombinant tissue-type plasminogen; Bleeding; complications; Incidence | ||
| References | ||
|
[1] R. Mehta and A. D. Shapiro, “Plasminogen deficiency,” Haemophilia, vol. 14, no. 6, pp. 1261–1268, 2008.
[2] P. Gurman, O. R. Miranda, A. Nathan, C. Washington, Y. Rosen, and N. M. Elman, “Recombinant tissue plasminogen activators (rtPA): a review,” Clin Pharmacol Ther, vol. 97, no. 3, pp. 274–285, 2015.
[3] D. Kireyev, H. C. Tan, and K. K. Poh, “Management of acute ST-elevation myocardial infarction: reperfusion options,” Ann Acad Med Singapore, vol. 39, pp. 927–933, 2010.
[4] P. Goldstein and E. Wiel, “Management of prehospital thrombolytic therapy in ST-segment elevation acute coronary syndrome (< 12 hours).,” Minerva Anestesiol., vol. 71, no. 6, pp. 297–302, 2005.
[5] G. H. Guyatt, E. A. Akl, M. Crowther, D. D. Gutterman, and H. J. Schuünemann, “Executive summary: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines,” Chest, vol. 141, no. 2 Suppl, p. 7S, 2012.
[6] G. Melandri, F. Vagnarelli, D. Calabrese, F. Semprini, S. Nanni, and A. Branzi, “Review of tenecteplase (TNKase) in the treatment of acute myocardial infarction,” Vasc. Health Risk Manag., vol. 5, p. 249, 2009.
[7] S. G. Goodman and W. J. Cantor, “Drip‑and‑ship for acute ST‑segment myocardial infarction,” Pol. Arch. Med. WEWNĘTRZNEJ, vol. 119, no. 11, pp. 726–730, 2009.
[8] J. Röther, G. A. Ford, and V. N. S. Thijs, “Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities,” Cerebrovasc. Dis., vol. 35, no. 4, pp. 313–319, 2013.
[9] A. Baratloo et al., “Tissue plasminogen activator: A literature review,” Arch Neurosci, vol. 3, no. 1, p. e30452, 2016.
[10] M. T. Mullen, J. M. Pisapia, S. Tilwa, S. R. Messé, and S. C. Stein, “Systematic review of outcome after ischemic stroke due to anterior circulation occlusion treated with intravenous, intra-arterial, or combined intravenous+ intra-arterial thrombolysis,” Stroke, vol. 43, no. 9, pp. 2350–2355, 2012.
[11] B. T. Bateman et al., “Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002,” Stroke, vol. 37, no. 2, pp. 440–446, 2006.
[12] K. B. Al-Kubaisi and M. B. Al-Rikabi, “THE EFFECT OF TISSUE PLASMINOGEN ACTIVATOR ON THE MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION,” IRAQI J. Med. Sci., p. 278, 2000.
[13] N. A. N. Muhamad, Mm. E. MbBcHBAO, M. S. Azizan, N. A. Masani, T. S. Ling, and O. T. Siang, “Asscociation of risk factors and its bleeding complication for tenecteplase administered in acute myocardial infarction (AMI),” Med J Malaysia, vol. 68, no. 5, p. 381, 2013.
[14] H.-H. ERLEMEIER, W. Zangemeister, L. Burmester, J. Schofer, D.-G. MATHEY, and W. Bleifeld, “Bleeding after thrombolysis in acute myocardial infarction,” Eur. Heart J., vol. 10, no. 1, pp. 16–23, 1989.
[15] S. D. Berkowitz et al., “Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction,” Circulation, vol. 95, no. 11, pp. 2508–2516, 1997.
[16] P. Pheerawong and B. Plienthaisong, “Outcome of recombinant tissue plasminogen activator in ST-segment elevation myocardial infarction in Buriram Hospital,” J Med Assoc Thail Chotmaihet Thangphaet, vol. 97, no. 8, pp. 804–811, 2014.
[17] L. M. Brass, J. H. Lichtman, Y. Wang, J. H. Gurwitz, M. J. Radford, and H. M. Krumholz, “Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project,” Stroke, vol. 31, no. 8, pp. 1802–1811, 2000.
[18] J. S. Balami, B. A. Sutherland, and A. M. Buchan, “Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke,” CNS Neurol. Disord. Targets (Formerly Curr. Drug Targets-CNS Neurol. Disord., vol. 12, no. 2, pp. 155–169, 2013.
[19] M. G. Lansberg, G. W. Albers, and C. A. C. Wijman, “Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors,” Cerebrovasc. Dis., vol. 24, no. 1, pp. 1–10, 2007.
[20] P. P. De Jaegere, A. A. Arnold, A. H. Balk, and M. L. Simoons, “Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors,” J. Am. Coll. Cardiol., vol. 19, no. 2, pp. 289–294, 1992.
[21] S. B. Soumerai, T. J. McLaughlin, D. Ross-Degnan, C. L. Christiansen, and J. H. Gurwitz, “Effectiveness of thrombolytic therapy for acute myocardial infarction in the elderly: cause for concern in the old-old,” Arch. Intern. Med., vol. 162, no. 5, pp. 561–568, 2002.
[22] A. K. BERGER et al., “Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients,” Surv. Anesthesiol., vol. 44, no. 3, pp. 136–137, 2000.
[23] B. G. Angeja, A. C. Rundle, J. H. Gurwitz, J. M. Gore, and H. V Barron, “Death or nonfatal stroke in patients with acute myocardial infarction treated with tissue plasminogen activator,” Am. J. Cardiol., vol. 87, no. 5, pp. 627–630, 2001.
[24] M. Martínez-Sellés, T. Datino, and H. Bueno, “Influence of reperfusion therapy on prognosis in patients aged≥ 89 years with acute myocardial infarction,” Am. J. Cardiol., vol. 95, no. 10, pp. 1232–1234, 2005.
[25] A. Carro and J. C. Kaski, “Myocardial infarction in the elderly,” Aging Dis., vol. 2, no. 2, p. 116, 2011. | ||
|
Statistics Article View: 121 PDF Download: 79 |
||